Prognostic Impact of Ki-67 Change in Locally Advanced and Early Breast Cancer after Neoadjuvant Chemotherapy: A Single Institution Experience

Table 3

Multivariate analysis (DFS).

Variable		HR	95% CI
Age (≤50 vs. >50)	0,6985	1,1786	0,5152 to 2,6961
Breast cancer molecular subtype	0,0348	1,4441	1,0283 to 2,0281
Clinical stage (II vs. III)	0,6204	1,1359	0,6878 to 1,8758
Lymphovascular invasion (absent vs. present)	0,3984	1,4311	0,6255 to 3,2745
Ki-67 change (pre- vs. post-NCT)	0,0256	0,5788	0,3589 to 0,9333

DFS, disease-free survival; HR, hazard ratio; CI, confidence interval; NCT, neoadjuvant chemotherapy.